<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.82037</article-id><article-id pub-id-type="publisher-id">ACM-24468</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180200000_17210012.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  房颤射频消融术术后复发相关因素研究进展
  Progress in Research on Factors of Atrial Fibrillation Recurrence after Radiofrequency Ablation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>美玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>青</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>尚郎</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>艳飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学院附属医院心血管内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>03</month><year>2018</year></pub-date><volume>08</volume><issue>02</issue><fpage>217</fpage><lpage>221</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    心房颤动(atrial fibrillation，房颤)是临床工作中最常见的心律失常之一，可引起血流动力学改变导致血栓事件发生，是房颤患者预后不良的重要原因。目前房颤的治疗主要为药物治疗和非药物治疗，药物治疗以控制心室率为主，非药物治疗有电转复、射频消融术。射频消融术是对药物治疗反应性差的病人恢复窦性心律的重要方法，被广泛应用于临床。手术常见并发症为射频消融术术后复发，研究房颤患者射频消融术术后复发的相关因素，识别复发的高危患者，有助于指导临床治疗。本研究就房颤患者射频消融术术后复发的相关因素进行概述。
    Atrial fibrillation (AF) is one of the most common arrhythmias in clinical work. It can cause he-modynamic change and lead to thrombotic events. It is an important cause of bad prognosis in pa-tients with atrial fibrillation. At present, the treatment of atrial fibrillation is drug treatment and non-drug treatment. Drug treatment mainly controls the ventricular rate, and non-drug treatment includes electrical conversion, radiofrequency ablation. Radiofrequency ablation is an important method for restoring sinus rhythm in patients with poor response to drug therapy. Radiofrequency ablation is widely used in clinical practice. The common complication of radiofrequency ablation is recurrence. Studying the relevant factors and identifying patients with high rate of recurrence will help to guide clinical treatment. This study outlines factors of atrial fibrillation recurrence after radiofrequency ablation. 
  
 
</p></abstract><kwd-group><kwd>综述，心房颤动，射频消融术，复发, Review</kwd><kwd> Atrial Fibrillation</kwd><kwd> Radiofrequency Ablation</kwd><kwd> Recurrence</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>房颤射频消融术术后复发相关因素研究进展<sup> </sup></title><p>杨美玲，赵青<sup>*</sup>，蔡尚郎，于艳飞</p><p>青岛大学医学院附属医院心血管内科，山东 青岛</p><p><img src="//html.hanspub.org/file/21-1570512x1_hanspub.png" /></p><p>收稿日期：2018年3月23日；录用日期：2018年4月16日；发布日期：2018年4月23日</p><disp-formula id="hanspub.24468-formula34"><graphic xlink:href="//html.hanspub.org/file/21-1570512x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>心房颤动(atrial fibrillation，房颤)是临床工作中最常见的心律失常之一，可引起血流动力学改变导致血栓事件发生，是房颤患者预后不良的重要原因。目前房颤的治疗主要为药物治疗和非药物治疗，药物治疗以控制心室率为主，非药物治疗有电转复、射频消融术。射频消融术是对药物治疗反应性差的病人恢复窦性心律的重要方法，被广泛应用于临床。手术常见并发症为射频消融术术后复发，研究房颤患者射频消融术术后复发的相关因素，识别复发的高危患者，有助于指导临床治疗。本研究就房颤患者射频消融术术后复发的相关因素进行概述。</p><p>关键词 :综述，心房颤动，射频消融术，复发</p><disp-formula id="hanspub.24468-formula35"><graphic xlink:href="//html.hanspub.org/file/21-1570512x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/21-1570512x8_hanspub.png" /> <img src="//html.hanspub.org/file/21-1570512x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>射频消融术是治疗快速性心律失常最有效的方法。房颤行射频消融术成功率约为60%~90% [<xref ref-type="bibr" rid="hanspub.24468-ref1">1</xref>] ，房颤复发定义为手术空白期之后心电图或24小时动态心电图记录到1次持续30 s以上的房性快速性心律失常(房颤、房扑或房速)。研究发现，左房大小、P波离散度、房颤类型、房颤持续时间、炎症因子等因素在房颤复发中起到一定作用 [<xref ref-type="bibr" rid="hanspub.24468-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.24468-ref3">3</xref>] 。众多因素已被研究，但没有哪个因素具有高度准确性。本文通过搜集国内外文献，概述部分房颤复发预测因素，帮助临床工作者建立完善的预测体系，选择复发率低、适合复律的患者，为患者提供最佳治疗方案。</p></sec><sec id="s4"><title>2. 房颤射频术后复发相关因素</title><sec id="s4_1"><title>2.1. 左心耳体积</title><p>射频消融术前左心耳体积可通过心脏增强CT准确测量，左心耳体积是房颤复发的独立危险因素，左心耳体积大的患者易发生房颤复发，左心耳体积 &gt; 8.80 ml时，预测房颤复发的敏感度和特异度最高 [<xref ref-type="bibr" rid="hanspub.24468-ref4">4</xref>] 。一项临床随机试验表明，左心耳电隔离可降低永久性房颤患者导管射频消融术后房性心律失常的发生率 [<xref ref-type="bibr" rid="hanspub.24468-ref5">5</xref>] 。左心耳由广泛的梳状肌和数层排列方向不同的肌束构成，复杂的结构使电信号传导减慢或者阻滞，形成折返，最终导致房颤。</p></sec><sec id="s4_2"><title>2.2. 中性粒细胞/淋巴细胞比值</title><p>中性粒细胞/淋巴细胞比值(neutrophil-to-lymphocyte ratio NLR)是一种新的全身炎症指标，中性粒细胞是体内非特异性炎症反应标志物，淋巴细胞则与体内氧化应激反应相关，NLR包含了两种白细胞亚型信息，反映了体内中性粒细胞与淋巴细胞水平的平衡状态，较单一指标更能反应全身性炎症状态。Acet等 [<xref ref-type="bibr" rid="hanspub.24468-ref6">6</xref>] 研究发现无论是阵发性房颤还是持续性、永久性房颤患者，NLR均高于对照组，NLR &gt; 2.1是房颤的独立危险因素，NLR与复发房颤直接相关，是合适有效的预测指标。NLR参与房颤复发机制主要为：1) NLR作为炎症因子参与房颤发生。2) NLR与左心房重构，研究发现NLR与左心房容积/体表面积(LAVi)呈正相关(p = 0.007, r = 0.247) [<xref ref-type="bibr" rid="hanspub.24468-ref7">7</xref>] ，LAVi可表示心房组织结构重构。NLR是相对容易使用的工具，可以提供预测房颤复发的附加信息，因此，血细胞检测对于具有高复发风险以及正在接受治疗的房颤患者特别重要。</p></sec><sec id="s4_3"><title>2.3. 血清球蛋白</title><p>心房重构是房颤的基本病理机制，自身免疫反应在重构过程中发挥重要作用，血清球蛋白水平是炎症和身体免疫状态的良好生物标志物。在免疫反应过程中，单核吞噬细胞合成和分泌血清球蛋白，炎症细胞因子和抗体是血清球蛋白的两个主要成分，它们参与了房颤的发病和复发。因此，血清球蛋白水平可能是预测房颤复发风险的血清学标记。研究证明，低水平的血清球蛋白，尤其是血清球蛋白水平 &lt; 25.4 g/L，对于房颤复发具有高度预测性 [<xref ref-type="bibr" rid="hanspub.24468-ref8">8</xref>] 。</p></sec><sec id="s4_4"><title>2.4. 二十二碳六烯酸(DHA)</title><p>不饱和脂肪酸通过调节细胞膜的磷脂双分子层和离子通道等机制发挥抗炎和抗纤维化作用。饮食管理治疗和应用他汀类药物等混杂因素可能会降低血浆DHA水平与房颤复发之间的相关性。研究发现无血脂异常患者血浆DHA水平与房颤复发之间显著相关 [<xref ref-type="bibr" rid="hanspub.24468-ref9">9</xref>] 。这一结果需要更大的研究队列重新评估。</p></sec><sec id="s4_5"><title>2.5. ZFHX3基因</title><p>家族性房颤多为单基因遗传疾病，而对于大多数散发性房颤(非家族性房颤)，常由基因的单个碱基改变引起，这种改变称为单核苷酸多态性(Single Nucleotide Polymorphisms, SNPs)。房颤发病机制和治疗的研究(GWAS)及其荟萃研究发现多个与房颤易感性显著相关的SNPs，位于ZFHX3基因。</p><p>JAK是一类非受体酪氨酸激酶家族，底物为STAT，即信号转导子和转录激活子，STAT被JAK磷酸化后发生二聚化，然后穿过核膜进入核内调节相关基因的表达，这条信号通路称为JAK-STAT途径。</p><p>ZFHX3与JAK-STAT信号通路有关，介导炎症过程，从而促进心房的电、结构重构。ZFHX3正向调节PITX2的表达，ZFHX3和PITX2均正向调节NPPA的表达。心房钠尿肽，NPPA产物可调节自主神经系统和调节心脏离子通道的功能。另外，ZFHX3和PITX2对下游基因(如TBX5，NKX2.5，KCNQ1和SCN1B)也有影响，这些基因在房颤的发病中起关键作用。其中，TBX5调节最近被发现可以改变心脏通道基因的表达，并导致小鼠原发性、自发性AF [<xref ref-type="bibr" rid="hanspub.24468-ref10">10</xref>] 。</p></sec><sec id="s4_6"><title>2.6. 人基质金属蛋白酶MMP-9、MMP-2</title><p>心房纤维化参与房颤的发生。在这个过程中，细胞外基质(ECM)起重要作用。心房ECM是由心房肌细胞合成、分泌，分布在细胞表面或细胞之间的大分子，主要是一些多糖和蛋白或蛋白聚糖。在生理状态下，ECM构成心肌的网架结构，支持并连接心肌组织、调节心房肌细胞的生理活动。病理状态下，ECM过度增生、沉积是心肌纤维化的重要原因 [<xref ref-type="bibr" rid="hanspub.24468-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.24468-ref12">12</xref>] 。MMP是降解ECM的蛋白水解酶系统，MMP水平异常时，ECM降解不平衡，导致心房结构重构 [<xref ref-type="bibr" rid="hanspub.24468-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.24468-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.24468-ref15">15</xref>] 。Nakano 等 [<xref ref-type="bibr" rid="hanspub.24468-ref16">16</xref>] 学者报道，对持续性房颤患者射频消融术术后进行随访，复发患者血清MMP-9、MMP-2水平显著高于未复发患者，是持续性房颤患者术后复发的独立预测因子。</p></sec><sec id="s4_7"><title>2.7. CRP、IL-6</title><p>导管射频消融术治疗房颤会导致患者心肌内膜、心包出现不同程度的损伤继而发生炎症反应。在炎症应答过程中T淋巴细胞、巨噬细胞会分泌大量的IL-6，然后由IL-6诱导产生CRP，两相指标的水平含量呈正相关关系，因此通过测定CRP含量情况则可以反应患者炎症情况。血液中CRP激活补体系统，进一步损伤心肌细胞，心肌细胞凋亡过度，加重纤维组织增生，从而促进心房结构重构。研究表明复发组患者术前的CRP、IL-6水平均显著高于未复发组 [<xref ref-type="bibr" rid="hanspub.24468-ref17">17</xref>] 。因此对于术前血液中IL-6、CRP水平较高患者，需要在消融治疗后积极制定预防复发的相关措施，如应用抗心律失常药物。</p></sec><sec id="s4_8"><title>2.8. NLRP3炎症小体</title><p>炎症小体活化是由多蛋白复合物组装信号介导的炎症相关的半胱氨酸天冬氨酸特异蛋白酶活化以及白细胞介素-1β(IL-1β)、白细胞介素-18(IL-18)等炎症因子的成熟过程。其中NOD (nucleotide binding oligomerization domain)样受体家族3(NOD-like receptors, NLRP3)炎症小体是目前研究最透彻的炎症小体类型，它参与了人类众多疾病的发生发展。</p><p>NLRP3炎症小体是由NLRP3、ASC及 Caspase-1组成，其中，Caspase-1是NLRP3炎性小体的效应蛋白，负责将无活性的 pro-IL-1β、pro-IL-18 切割成为具有活性的IL-1β、IL-18，进而激活下游炎性介质，导致机体局部或全身发生严重的炎症反应。IL-1β作为NLRP3炎性小体激活的主要产物，可以引起心肌细胞增生肥大、凋亡，刺激成纤维细胞增殖，影响间质胶原的代谢。在动物实验中通过抑制IL-1β的表达，可以减轻胶原增生、改善心肌重塑 [<xref ref-type="bibr" rid="hanspub.24468-ref18">18</xref>] 。由此可见，IL-1β可能通过炎症反应促使心脏结构重构和(或)电重构，导致房颤的发生、发展。房颤患者外周血NLRP3炎症小体及其下游因子水平升高与房颤之间密切相关，可能成为房颤治疗的潜在靶点，但需大样本、多中心的研究进一步确定NLRP3炎症小体与房颤的关系。</p></sec><sec id="s4_9"><title>2.9. 转化生长因子β1(TGFβ1)</title><p>反应心肌纤维化的指标很多，如Ⅲ型前胶原末端肽(P III P)、Ⅳ型前胶原末端肽(P IV P)、层粘连蛋白 (LN)、透明质酸(HA)及转化生长因子β1(TGFβ1)等。Verheuie等 [<xref ref-type="bibr" rid="hanspub.24468-ref19">19</xref>] 通过转基因技术过度合成TGFβ1，发现TGFβ1过度表达组小鼠心房纤维化加重，房颤的诱发率显著增加，TGFβ1是预测心房纤维化的独立危险因素，同时通过多元回归分析，发现术前血浆TGFβ1水平与阵发性和持续性房颤导管消融术后复发均有显著关系。上述结果需更多研究证实。</p></sec></sec><sec id="s5"><title>3. 结论</title><p>综上所述，左心耳体积、NRL、血清球蛋白、DHA、MMP-9、MMP-2、NLRP3炎症小体、CRP、IL-6、转化生长因子β1(TGFβ1)、ZFHX3等因素与房颤发生有关，因此在实际临床工作中，我们可以适当选取一些便捷有效的指标，为患者建立房颤射频消融术术后复发风险预测体系，评估复发风险高低，权衡利弊，使治疗个体化，为患者选择更加合适的治疗方案。同时筛选术后高复发风险患者，通过增加药物干预或者增加随访次数，将复发率降至最低。</p></sec><sec id="s6"><title>文章引用</title><p>杨美玲,赵 青,蔡尚郎,于艳飞. 房颤射频消融术术后复发相关因素研究进展 Progress in Research on Factors of Atrial Fibrillation Recurrence after Radiofrequency Ablation[J]. 临床医学进展, 2018, 08(02): 217-221. https://doi.org/10.12677/ACM.2018.82037</p></sec><sec id="s7"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24468-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Arbelo, E., Brugada, J., Hindricks, G., et al. (2014) The Atrial Fibrillation Ablation Pilot Study: A European Survey on Methodology and Results of Catheter Ablation for Atrial Fibrillation Conducted by the European Heart Rhythm Asso-ciation. European Heart Journal, 35, 1466-1478. https://doi.org/10.1093/eurheartj/ehu001</mixed-citation></ref><ref id="hanspub.24468-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">陶惠伟, 刘少稳, 林佳雄, 等. P波离散度与阵发性房颤经导管射频消融术后复发的关系[J]. 中国临床医学, 2009, 16(4): 498-500.</mixed-citation></ref><ref id="hanspub.24468-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">武冰琳, 汪祥海. 炎症因子与心房颤动消融术后复发的关系[J]. 临床荟萃, 2016, 31(9): 1038-1041.</mixed-citation></ref><ref id="hanspub.24468-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">郑桂安, 林春艺, 翁兰, 等. 左心耳体积对心房颤动导管射频消融术后复发的预测价值[J]. 中华心血管病杂志, 2017, 45(11): 924-929.</mixed-citation></ref><ref id="hanspub.24468-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Di, B.L., Burkhardt, J.D., Mohanty, P., et al. (2016) Left Atrial Ap-pendage Isolation in Patients with Longstanding Persistent AF Undergoing Catheter Ablation: BELIEF Trial. Journal of the American College of Cardiology, 68, 1929-1940. https://doi.org/10.1016/j.jacc.2016.07.770</mixed-citation></ref><ref id="hanspub.24468-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Acet, H., Ertaş, F., Akıl, M.A., et al. (2014) New Inflammatory Predictors for Non-Valvular Atrial Fibrillation: Echocardiographic Epicardial Fat Thickness and Neutrophil to Lymphocyte Ratio. International Journal of Cardiovascular Imaging, 30, 81-89. https://doi.org/10.1007/s10554-013-0317-4</mixed-citation></ref><ref id="hanspub.24468-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sonmez, O., Ertem, F.U., Vatankulu, M.A., et al. (2014) Novel Fibro-Inflammation Markers in Assessing Left Atrial Remodeling in Non-Valvular Atrial Fibrillation. Medical Science Monitor International Medical Journal of Experimental &amp; Clinical Research, 20, 463-470.</mixed-citation></ref><ref id="hanspub.24468-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Q., Cao, H., Xu, Z., et al. (2017) Baseline Serum Globulin as a Predictor of the Recurrence of Lone Atrial Fibrillation after Radiofrequency Catheter Ablation. The Anatolian Journal of Cardiology, 17, 381-385.</mixed-citation></ref><ref id="hanspub.24468-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Shiozawa, T., Shimada, K., Sekita, G., et al. (2017) Left Atrial Appendage Volume and Plasma Docosahexaenoic Acid Levels Are Associated With Atrial Fibrillation Recurrence After Catheter Ablation. Cardiology Research, 8, 96-104.  
https://doi.org/10.14740/cr542w</mixed-citation></ref><ref id="hanspub.24468-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nadadur, R.D., Broman, M.T., Boukens, B., et al. (2016) Pitx2 Modulates a Tbx5-Dependent Gene Regulatory Network to Maintain Atrial Rhythm. Science Translational Medicine, 8, 354ra115.  
https://doi.org/10.1126/scitranslmed.aaf4891</mixed-citation></ref><ref id="hanspub.24468-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yue, L., Xie, J. and Nattel, S. (2011) Molecular Determinants of Cardiac Fibroblast Electrical Function and Therapeutic Implications for Atrial Fibrillation. Cardiovascular Research, 89, 744-753. https://doi.org/10.1093/cvr/cvq329</mixed-citation></ref><ref id="hanspub.24468-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chiu, Y.-T., Wu, T.-J., Wei, H.-J., et al. (2005) Increased Extracellular Collagen Matrix in Myocardial Sleeves of Pulmonary Veins: An Additional Mechanism Facilitating Repetitive Rapid Activities in Chronic Pacing-Induced Sustained Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 16, 753.  
https://doi.org/10.1046/j.1540-8167.2005.40794.x</mixed-citation></ref><ref id="hanspub.24468-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">董丽君, 汤宝鹏, 周贤惠, 等. 心房肌基质金属蛋白酶及其抑制剂、凋亡相关基因表达改变与增龄性心房颤动关系的研究[J]. 中国循环杂志, 2014(12): 1034-1038.</mixed-citation></ref><ref id="hanspub.24468-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Gallegocolon, E., Sampson, R.D., Sattler, S., et al. (2015) Cardiac-Restricted IGF-1Ea Overexpression Reduces the Early Accumulation of Inflammatory Myeloid Cells and Mediates Expression of Extracellular Matrix Remodelling Genes after Myocardial Infarction. Mediators of Inflammation, 2015, Article ID: 484357.</mixed-citation></ref><ref id="hanspub.24468-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Moe, G.W., Laurent, G., Doumanovskaia, L., et al. (2008) Matrix Metalloproteinase Inhibition Attenuates Atrial Remodeling and Vulnerability to Atrial Fibrillation in a Canine Model of Heart Failure. Journal of Cardiac Failure, 14, 768-776. https://doi.org/10.1016/j.cardfail.2008.07.229</mixed-citation></ref><ref id="hanspub.24468-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Nakano, Y., Niida, S., Dote, K., Takenaka, S., Hirao, H., Miura, F., Ishida, M., Shingu, T., Sueda, T., Yoshizumi, M. and Chayama, K. (2004) Matrix Metalloproteinase-9 Contributes to Human Atrial Remodeling during Atrial Fibrillation. Journal of the American College of Cardiology, 43, 818-825. https://doi.org/10.1016/j.jacc.2003.08.060</mixed-citation></ref><ref id="hanspub.24468-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Bracey, N.A., Beck, P.L., Muruve, D.A., et al. (2013) The Nlrp3 Inflammasome Promotes Myocardial Dysfunction in Structural Cardiomyopathy through Interleukin-1β. Experimental Physiology, 98, 462.  
https://doi.org/10.1113/expphysiol.2012.068338</mixed-citation></ref><ref id="hanspub.24468-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">李彬, 廖玉华, 程翔, 等. 卡维地洛对心肌梗死后大鼠心肌IL-1β表达及胶原沉积的影响[J]. 中华医学杂志, 2005, 85(6): 416-418.</mixed-citation></ref><ref id="hanspub.24468-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Verheule, S., Sato, T., Everett, T., et al. (2004) Increased Vulnerability to Atrial Fibrillation in Transgenic Mice with Selective Atrial Fibrosis Caused by Overexpression of TGF-β1. Circulation Research, 94, 1458-1465.  
https://doi.org/10.1161/01.RES.0000129579.59664.9d</mixed-citation></ref></ref-list></back></article>